share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  09/09 16:32

Moomoo AI 已提取核心信息

On September 5, 2024, 180 Life Sciences Corp. entered into a Separation and Release Agreement with Sir Marc Feldmann, its former Co-Executive Chairman and CEO of its subsidiary Cannbiorex Pharma Ltd., as well as a current director. The agreement includes the issuance of 57,328 shares of common stock and options to purchase 20,000 shares at $1.95 per share to Sir Feldmann. These are to be issued under the company's incentive plan as compensation for past services. Additionally, Sir Feldmann has agreed to confidentiality and non-disparagement covenants. Concurrently, an Indemnification Agreement was made to provide Sir Feldmann with indemnification under Delaware law for his service to the company. Following the stock issuance to Sir Feldmann, 180 Life Sciences will have 1,026,930 shares of common stock issued and outstanding.
On September 5, 2024, 180 Life Sciences Corp. entered into a Separation and Release Agreement with Sir Marc Feldmann, its former Co-Executive Chairman and CEO of its subsidiary Cannbiorex Pharma Ltd., as well as a current director. The agreement includes the issuance of 57,328 shares of common stock and options to purchase 20,000 shares at $1.95 per share to Sir Feldmann. These are to be issued under the company's incentive plan as compensation for past services. Additionally, Sir Feldmann has agreed to confidentiality and non-disparagement covenants. Concurrently, an Indemnification Agreement was made to provide Sir Feldmann with indemnification under Delaware law for his service to the company. Following the stock issuance to Sir Feldmann, 180 Life Sciences will have 1,026,930 shares of common stock issued and outstanding.
2024年9月5日，180 Life Sciences Corp.与其前联合主席和其子公司Cannbiorex Pharma Ltd.的首席执行官Marc Feldmann爵士签订了一份分离和解除协议，亦为公司董事之一。协议包括向Feldmann爵士发行57,328股普通股和购买20,000股每股价格为1.95美元的期权。这些股票和期权将根据公司的激励计划发行，作为对过去服务的补偿。此外，Feldmann爵士还同意遵守保密和非诋毁条款。与此同时，根据特拉华州法律，还签订了一份赔偿协议，为Feldmann爵士提供赔偿。在股票发行给Feldmann爵士之后，180 Life Sciences将有1,026,930股普通股发行和流通。
2024年9月5日，180 Life Sciences Corp.与其前联合主席和其子公司Cannbiorex Pharma Ltd.的首席执行官Marc Feldmann爵士签订了一份分离和解除协议，亦为公司董事之一。协议包括向Feldmann爵士发行57,328股普通股和购买20,000股每股价格为1.95美元的期权。这些股票和期权将根据公司的激励计划发行，作为对过去服务的补偿。此外，Feldmann爵士还同意遵守保密和非诋毁条款。与此同时，根据特拉华州法律，还签订了一份赔偿协议，为Feldmann爵士提供赔偿。在股票发行给Feldmann爵士之后，180 Life Sciences将有1,026,930股普通股发行和流通。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间